Person
Simon Jan Middendorp
This person is no longer with EPFL
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Related publications (5)
Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.
Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
Christian Heinis, Xudong Kong, Jonas Alfred Karl Wilbs, Patrick Andreas Gonschorek, Simon Jan Middendorp, Christina Lamers
Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or inhibition in animals reduced thrombosis without causing abnorma ...
2020Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity
Christian Heinis, Jonas Alfred Karl Wilbs, Simon Jan Middendorp
Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or prevent pathological thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling disorder hereditary angioedema ...
2017Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
Christian Heinis, Alessandro Zorzi, Jonas Alfred Karl Wilbs, Simon Jan Middendorp
The rapid renal clearance of peptides in vivo limits this attractive platform for the treatment of a broad range of diseases that require prolonged drug half-lives. An intriguing approach for extending peptide circulation times works through a 'piggy-back' ...
2017